Management of PPI-Refractory Gastritis with Epigastric Pain and Early Satiety
For this patient with endoscopically-confirmed gastritis that has failed PPI therapy, test for H. pylori and provide eradication therapy if positive, then initiate a tricyclic antidepressant (starting with amitriptyline 10 mg nightly, titrating to 30-50 mg) as second-line neuromodulator therapy. 1
Diagnostic Priorities
First, confirm H. pylori status if not already done. Use either fecal antigen or carbon-urea breath testing—not serology, which has lower specificity 1. This is critical because:
- H. pylori eradication is highly efficacious for functional dyspepsia with strong evidence 1
- Approximately 5% of dyspepsia is attributable to H. pylori infection 1
- Even with visible gastritis on endoscopy, H. pylori treatment can resolve both inflammation and symptoms
Treatment Algorithm
If H. pylori Positive:
- Provide eradication therapy immediately (strong recommendation, high-quality evidence) 1
- This addresses both the gastritis and functional dyspepsia symptoms
- No need to confirm eradication unless the patient has increased gastric cancer risk 1
If H. pylori Negative or Symptoms Persist After Eradication:
Since PPI therapy has already failed, move directly to second-line treatment with tricyclic antidepressants 1:
- Start amitriptyline 10 mg once daily at bedtime
- Titrate slowly to 30-50 mg daily based on response
- These work as gut-brain neuromodulators, not antidepressants
- Strong recommendation with moderate-quality evidence 1
Critical counseling point: Explain clearly that TCAs are being used for pain modulation and visceral hypersensitivity, not depression. This explanation is essential for adherence 1, 2.
Alternative Second-Line Options
If TCAs are contraindicated or not tolerated:
- Prokinetics (acotiamide, itopride, mosapride, or tegaserod if available) may help, particularly given the early satiety suggesting delayed gastric emptying 1, 3
- Antipsychotics (sulpiride 100 mg four times daily or levosulpiride 25 mg three times daily) as alternative neuromodulators 1
What NOT to Do
- Do not increase PPI dose—there is no dose-response relationship for functional dyspepsia, and doubling PPIs shows no additional benefit 1, 4
- Avoid opioids completely—these should never be prescribed for chronic gastrointestinal pain in disorders of gut-brain interaction 2
- Do not routinely order gastric emptying studies or 24-hour pH monitoring for typical functional dyspepsia symptoms 1
Adjunctive Measures
While initiating pharmacotherapy:
- Recommend regular aerobic exercise (strong recommendation) 1
- Consider trial of H2-receptor antagonists if not yet attempted (weak recommendation, but well-tolerated) 1
- Early dietitian involvement to prevent overly restrictive eating patterns, especially given the early satiety 1
If Symptoms Remain Refractory
For severe or refractory cases despite the above:
- Involve multidisciplinary support team 1
- Screen for eating disorders, including avoidant restrictive food intake disorder (ARFID), particularly with weight loss and food restriction 1
- Consider gut-directed psychological therapies (cognitive behavioral therapy, hypnotherapy) 1, 2
- Maintain neuromodulator therapy for 6-12 months if there is response 5
Common Pitfalls to Avoid
The pain improving after eating suggests possible ulcer-like pattern, but since endoscopy shows only gastritis (not ulcer), this is likely functional dyspepsia with postprandial distress syndrome features. The key mistake would be continuing to escalate acid suppression when the evidence clearly shows PPIs have no dose-response effect in functional dyspepsia 1. Moving to neuromodulators addresses the underlying visceral hypersensitivity and central pain processing that perpetuates symptoms despite mucosal healing 2.